Fulvestrant
Fulvestrant is an active ingredient of the class «estrogen antagonist».
Chemical compound, synthetic estrogen receptor antagonist
What it is used for
- Breast cancer
- Breast neoplasm
- Neoplasm
Monotherapy CLIGAVYX is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal…
Faslodex is indicated as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: not previously treated with endocrine therapy, or with disease relapse on or after adjuvant antiestrogen therapy, or…
How it works
- Estrogen receptor alpha antagonist
- Estrogen receptor degrader
Class: estrogen antagonist
Common side effects
The following adverse reactions are discussed in more detail in other sections of the labeling: Risk of Bleeding Injection Site Reaction Embryo-Fetal Toxicity The most common adverse reactions occurring in ≥5% of patients receiving fulvestrant 500 mg were: injection site pain, nausea, bone pain, arthralgia, headache…
Who should not take it
CLIGAVYX is contraindicated in patients with a known hypersensitivity to the drug or to any of its components. Hypersensitivity reactions, including urticaria and angioedema, have been reported in association with CLIGAVYX. Hypersensitivity.
Pregnancy and breastfeeding
Based on findings from animal studies and its mechanism of action, CLIGAVYX can cause fetal harm when administered to a pregnant woman. There are no available data in pregnant women to inform the drug-associated risk.
Interactions
Brand names
United States
Cligavyx · Faslodex
European Union
Faslodex · Fulvestrant Mylan
Canada
Apo-Fulvestrant · Faslodex · Fulvestrant Injectable · Teva-Fulvestrant
Approval status
- US Food and Drug Administration
- prescription · since 2002
- European Medicines Agency
- authorised · since 2004
- Health Canada
- prescription · marketed
- First approval anywhere
- 2002
Codes
- ATC
- L02BA03
- RxNorm CUI
- 282357
- ChEMBL
- CHEMBL1358
- PubChem CID
- 104741
- UNII
- 22X328QOC4
- Wikidata
- Q5508491
Frequently asked questions
What is Fulvestrant used for?
Fulvestrant is used for: Breast cancer, Breast neoplasm, and Neoplasm.
What kind of medicine is Fulvestrant?
Fulvestrant is an active ingredient of the class «estrogen antagonist».
What are the brand names of Fulvestrant?
Brand names of Fulvestrant include Cligavyx, Faslodex, Fulvestrant Mylan, Apo-Fulvestrant, Fulvestrant Injectable, and Teva-Fulvestrant.
Medicines in the same class
Sources and licences
- ChEMBL (CC BY-SA 3.0)
- Wikidata (CC0 1.0)
- openFDA / DailyMed (public domain)
- European Medicines Agency (reuse with acknowledgement)
- Health Canada Drug Product Database (Open Government Licence – Canada)